San Francisco Bay Area | May 15-16, 2023

Image

Following the success of the 2nd Annual Psychedelic Therapeutics and Drug Development Conference in 2022, we're thrilled to be hosting the 3rd Annual event on May 15-16, 2023 in the San Francisco Bay Area. This event has been organized to bring together the world’s leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.

Our speakers and panelists will be covering important topics such as Clinical Trial Design, Intellectual Property, Regulatory Guidance, Psychedelic Drug Delivery, Commercialization, Legal Issues, Emerging Preclinical Science, and New Clinical Data among other topics. This event has been designed and curated for the benefit of key stakeholders in this burgeoning area and will provide practical guidance, discussion and networking.

Conference Themes

  • Clinical trial design
  • Risk Evaluation & Mitigation Strategy (REMS)
  • Abuse potential
  • Practical use/indications
  • DEA licensure & policy considerations
  • Targets for novel drug development
  • Dosage (micro/low/high)
  • Second generation psychedelic drug design
  • FDA regulatory guidance
  • Toxicology studies and considerations

2023 Featured Speakers

Elliot Marseille, DrPH, MPP
Elliot Marseille, DrPH, MPP
Director, UC Berkeley/UCSF Global Initiative for Psychedelic Science Economics
Joshua Woolley, MD, Ph.D.
Joshua Woolley, MD, Ph.D.
Associate Professor, Psychiatry, UCSF Weill Institute for Neurosciences
Gul Dolen, MD, Ph.D.
Gul Dolen, MD, Ph.D.
Associate Professor of Neuroscience, Brain Institute, Wendy Klag Center, Johns Hopkins University
Gitte Knudsen, MD, DMSc
Gitte Knudsen, MD, DMSc
Professor, Chair of Neurobiology Research Unit, Rigshospitalet, Chair of Center for Experimental Medicine Neuropharmacology, University of Copenhagen
Jaspreet Grewal
Jaspreet Grewal
Chief Executive Officer & Co-Founder, Knowde Group

Director, Capital Markets Shape Capital

Reasons to Attend

Discover, Learn & Understand

Learn about the latest developments in the field of psychedelics research and better understand the clinical path forward.

Meet, Network and Re-connect

Utilize our mobile & web-based platforms to set up meetings & connect with colleagues before, during and after the event.

Navigate Regulatory & Policy Challenges

Learn about the regulatory, legal and policy challenges facing developers of psychedelic-based therapies and formulate strategies.

2023 Conference Sponsors

Cayman
Worldwide
Hunte+Esquire
Westwood

2023 Conference Partners

AxialBridge
Psychedelic Alpha
CURA
Blossom
HowToLaunch

Conference Testimonials

There was an excellent selection of speakers who covered a broad range of topics all of which are relevant for anyone working on the development of a psychedelic medicine.
Judy Ashworth, MD, Vice President, Rx Strategic Services & Chief Medical Officer, Pinney Associates
It was a great meeting--had excellent interactions with other attendees.
Brian Roth, MD, Ph.D., Michael Hooker Distinguished Professor, University of North Carolina School of Medicine
I work for a CRO CNS clinical drug development and was enlightened to the extensive amount of psychedelic drug development that occurred before 2000 as well as to the breadth of science being done now. The heavy-hitters on the speaker list was impressive and made it clear this conference was a legitimate event. I will plan to attend next year in person. Also the technology for the speakers and the Q&A was excellent - best format I've seen for a large online meeting in the past year. Also being able to access the sessions after the conference through July is incredibly helpful. Thank you!
2021 Conference Attendee
For anyone interested in entering this therapeutic area from a research perspective, this is a great way to get a broad overview of the players, science, risk/benefits and training applicable to determine if this area is right for your involvement.
Leslie Franceschi, Syneos Health
Time well spent. Very informative.
August R. Buchhalter, Director, Abuse Potential Assessment, Pinney Associates

Past Attendees

AB Research - Acadia Pharmaceuticals - Adena Medical Center - Advanced Brain Monitoring - AHT Insurance - Albert Labs - Alberta Health Services - Ambria Capital - American Foundation for Suicide Prevention - Apex Innovative Sciences - Apollo Pact - April 19 Discovery - Atai Life Sciences - Beckley Psytech - Benchmark Research - Bexson Biomedical - BGI - Billings Clinic - BioPharma Services - Blue Matter - Bright Minds - CaamMTech - Care New England - CAS Center for Excellence in Molecular Cell Science - Catholic Charities - Cayman Chemical - Central Michigan University - Centricity Research - Certara - Clearmind Medicine - Clusterbusters - CNS Healthcare - CNS Network - Cognesy Therapeutics - Cohen Veterans Bioscience - Columbia University - COMPASS Pathways - Cybin - D'Or Institute of Research & Education - Daewoong Pharmaceutical - DARPA - Delix Therapeutics - Department of Defense - DevelRx - Eleusis - Emerge Law Group - Emory University - Empyrean Neuroscience - Entheon Biomedical - ESSENCE, World Health Organization - Exscientia - Feldman Legal Advisors - Fenix Group International - FieldTrip Health - Filament Health - FVE Foundry - GenTech Scientific - George Washington University - Georgetown University - Ghent University - Gilgamesh Pharmaceutical - H.C. Wainwright & Co. - Halloran Consulting Group - Halucenex Life Sciences - Harvard Bioscience - Hawaii Pacific University - HRI TRIALS - Husch Blackwell - ICBHS - IINFACTS - Indiana University South Bend - Instituto Phaneros - Jam of a Lifetime - Jazz Pharmaceuticals - Johns Hopkins School of Medicine - Johns Hopkins University - Journey Colab - Knowde Group - KPMG - LewisGale Medical Center - LSU Health New Orleans - LSU Health Sciences Center - Lucid News/Medium - MagicMed Industries - MAPS - MAPS Public Benefit Corporation - McGill University - McMaster University - McMaster University - Me-Med Diagnostics - Medical College of Wisconsin - Mental Wellness United - Michigan State University - Mind Cure - Mind Medicine - MindBio Therapeutics - MindMed - Mindset Pharma - Monash University - Multidisciplinary Association for Psychedelic Studies (MAPS) - Mydecine Innovations Group - Nanome - National Institute on Drug Abuse, IRP - NeonMind - NFP - NIH/NIDA - NIH/NIMH - NIH/NINDS - Noetic Foundry - Noeticfund - Nomon Bio - Northwestern Kellogg School of Management - Novartis - Numinus - NYU Langone Health Center for Psychedelic Medicine - Optimum Clinical Research Group - Origin Therapeutics Holdings - Penn State Health - Phillips Lytle LLP - Phoenix VA Health Care System - Phyto Partners - Pinney Associates - Promises Innovative Recovery - Psilera Bioscience - Psychedelic Alpha - Psychedelic Pharmacists Association - Purdue University - PurMinds NeuroPharma - Reaching Everyone In Distress Foundation - REID Foundation - RIVIA Mind - RMPDC Consulting - Roche - Rocky Mountain Poison and Drug Safety - Rutgers University - SBCC - Segal Trials - Shape Capital - SSI Strategy - St Lukes Medical Center - Stanford University School of Medicine - Stealth Biotech - Stifel - Syneos Health - Tata Institute of Fundamental Research - Terran Biosciences - Texas Tech University - The Apollo Project - The Conscious Fund - The Emmes Company - Tools4Patient - Touro University Nevada - TP Bioventures Limited - Transcend Therapeutics - Transliminal LLC - Tulane University - Twin Flames Psychotherapy - UC Davis - UC Davis Neuroscience Grad Group - UCLA - UCSF - UNC Eshelman School of Pharmacy - United States Food and Drug Administration - University College Dublin - University of Alabama Birmingham - University of Bath - University of California, Davis - University of Central Florida - University of Colorado Anschutz Medical Campus - University of Colorado School of Medicine - University of Copenhagen - University of Hawaii - University of Maryland School of Medicine - University of Nevada Las Vegas - University of North Carolina School of Medicine - University of Ottawa - University of Pennsylvania, Perelman School of Medicine - University of Rochester School of Medicine and Dentistry - University of Southern California - University of Texas Medical Branch - University of the Basque Country - University of Wisconsin-Madison - University of Wyoming - UTMB - UW-Madison - Vaidya lab -Tata Institute of Fundamental Research and KHS-MRC Alliance - Virginia Commonweath University - Virginia Tech - Wesana Health - Western Oregon University - Wetzel Chemistry Consulting - Wilmington University - Womack Army Medical Center - Woodline Partners - Worldwide Clinical Trials - Yale Universisty - Zuber Lawler

Who Should Attend

Chief Executive Officers
Vice Presidents
Chief Medical Officers
Business Development Professionals
Regulatory Affairs Professionals
Research Scientists
R&D Professionals
Clinical Development Professionals
Licensing Professionals
Investigators
Medical Chemists
Chemists
Pharmacists
Scientists
Study Managers
Project Managers
Scientific Officers
Professors
Ph.D./Pharm.D. Students
Health Care Practitioners
Program Officers
Investors
Analysts
Medical Directors

About Us

Arrowhead Conferences offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward.

READ MORE

Contact Details

Phone:
+1 866-945-0263

Email:
enquiries@arrowheadpublishers.com

Organized By